Pure Global
NCT06145347

Correlation Between Preoperative NT-proBNP and Postoperative AKI

Correlation Between the Preoperative N-terminal Pro-B-type Natriuretic Peptide and Acute Kidney Injury After Abdominal Surgery: a Single Center Retrospective Cohort Study Based on ERAS Database
Xijing Hospital·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Acute Kidney Injury
Study type
Observational
Sponsor & location
Primary sponsor
Xijing Hospital
Location
Xi'an, China
Timeline & enrollment
Phase
N/A
Start date
Jul 10, 2023
End date
Jan 31, 2024
Enrollment
633 participants
Primary outcome

Incidence of AKI assessed by KDIGO 2012 (Kidney Disease: Improving Global Outcomes)

Summary

Accurate preoperative AKI risk prediction is of great significance for improving patient
 outcomes. The use of preoperative NT-proBNP can provide a more precise assessment of the
 body's fluid load status, guide intraoperative and postoperative fluid management, and thus
 reduce fluid related postoperative complications. Given the potential association between
 ERAS and increased postoperative AKI, we hypothesize that preoperative NT-proBNP may be
 associated with the development of postoperative AKI in ERAS, and can improve the prediction
 of AKI beyond traditional clinical risk factors. This study aims to validate this hypothesis
 and provide evidence for using NT-proBNP to assess AKI risk before non cardiac surgery.
 Improve the predictive ability of clinical predictive models and optimize ERAS protocols to
 prevent postoperative AKI.

ICD-10 classifications
Injury of kidneyAcute renal failureAcute renal failure, unspecifiedOther acute renal failureAcute renal failure with tubular necrosis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06145347
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06145347 through Pure Global AI's free database. This phase not specified trial is sponsored by Xijing Hospital and is currently Recruiting. The study focuses on Acute Kidney Injury. Target enrollment is 633 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.